Evidence map›Paper›PMID 37705793›Full record

ArticleNanoscale advances2023

Regulating the surface topography of CpG nanoadjuvants

Li Zhang, Lingpu Zhang, Yuqi Wang, Kai Jiang, Chao Gao, Pengfei Zhang, Yujie Xie, Bin Wang, Yun Zhao, Haihua Xiao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Li ZhangSchool of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences Hangzhou Zhejiang 310024 China.
Lingpu ZhangBeijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences Beijing 100190 China.
Yuqi WangInstitute of Nano Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University Shanghai 200240 China sjie@sjtu.edu.cn.
Kai JiangInstitute of Nano Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University Shanghai 200240 China sjie@sjtu.edu.cn.
Chao GaoInstitute of Nano Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University Shanghai 200240 China sjie@sjtu.edu.cn.
Pengfei ZhangHangzhou Institute of Medicine, Chinese Academy of Sciences Hangzhou Zhejiang 310022 China.
Yujie XieSchool of Chemistry, University of Birmingham Edgbaston Birmingham B15 2TT UK.ORCID https://orcid.org/0000-0002-6024-7019
Bin WangBeijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences Beijing 100190 China.
Yun ZhaoSchool of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences Hangzhou Zhejiang 310024 China.
Haihua XiaoBeijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences Beijing 100190 China.ORCID https://orcid.org/0000-0001-8159-8187
Jie SongHangzhou Institute of Medicine, Chinese Academy of Sciences Hangzhou Zhejiang 310022 China.ORCID https://orcid.org/0000-0003-0816-7131

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoadjuvants play a key role in enhancing the efficacy of therapeutic tumor vaccines for treating malignant and recurrent cancers. However, due to the bottleneck in the rational design and mechanistic understanding of novel adjuvants, currently available immunoadjuvants in clinical practice are very limited. To boost adjuvant design and development, herein we propose a surface topography regulatory strategy for constructing novel adjuvants with improved adjuvant properties. One of the licensed adjuvants with a well-defined molecular mechanism of immune activation, cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODNs), was used as the material framework. We constructed immunostimulatory CpG nanoparticles (CpG NPs) with different surface topographies by coordination-driven self-assembly between CpG ODNs and ferrous ions. These self-assembled CpG NPs combine the biological and physical activation abilities of innate immunity and can be used as adjuvants of tumor antigens for malignant tumor immunotherapy. The experimental results showed that these CpG NPs could rapidly enter innate immune cells and remold the tumor microenvironment (TME) to enhance anti-tumor immunotherapy

Identifiers

PMID37705793
PMCPMC10496906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.